Welcome to our dedicated page for Ultragenyx Pharm news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharm stock.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a biopharmaceutical company focused on novel therapies for serious rare and ultra-rare genetic diseases. The RARE news feed highlights company announcements on commercial performance, clinical development, and key corporate decisions that shape its rare disease portfolio.
Investors and followers of Ultragenyx can find updates on revenue trends from its approved products Crysvita, Dojolvi, Mepsevii, and Evkeeza in select territories, as well as guidance ranges and commentary on operating expenses and cash position. Earnings-related press releases and Form 8-K summaries detail product sales, royalty revenue, and royalty financing transactions, including agreements involving future Crysvita royalties with OMERS.
The news stream also covers Ultragenyx’s late-stage pipeline and regulatory milestones. Readers can track progress of AAV gene therapy programs such as DTX401 for glycogen storage disease type Ia, UX111 for Sanfilippo syndrome type A, and UX701 for Wilson disease, along with monoclonal antibody UX143 for osteogenesis imperfecta and antisense oligonucleotide GTX-102 for Angelman syndrome. Company releases describe Phase 3 study results, longer-term follow-up data, regulatory designations, rolling BLA submissions, and responses to FDA communications such as Complete Response Letters.
In addition, the RARE news page features items on conference presentations, investor events, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). By reviewing these updates, users can follow how Ultragenyx manages its commercial portfolio, advances its clinical pipeline, and executes financing and collaboration strategies in the rare and ultra-rare disease space.
Ultragenyx Pharmaceutical reported Q2 2022 total revenue of $89.3 million, with Crysvita revenue at $64.0 million. They reaffirmed 2022 revenue guidance for Crysvita between $250 million and $260 million and Dojolvi between $55 million and $65 million. The company completed a $500 million royalty interest sale for Crysvita. Operating expenses reached $230.9 million, leading to a net loss of $158.2 million. The firm continues to develop its extensive pipeline, including late-stage products for various rare diseases.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will host a conference call on July 28, 2022, at 5:00 PM ET to discuss its financial results and corporate updates for Q2 2022. The call will be available via live webcast on the company's website. Ultragenyx focuses on developing therapies for rare genetic diseases, boasting a portfolio of approved medicines and candidates for unmet medical needs. The company emphasizes efficient drug development to deliver timely therapies to patients.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced on July 20, 2022, the grant of stock options for 10,240 shares and 5,120 restricted stock units to a newly hired non-executive officer. These awards, part of the Ultragenyx Employment Inducement Plan, were approved by the compensation committee. The stock options have a ten-year term with an exercise price of $64.75 per share. The restricted stock units and options have a vesting schedule of four years, contingent on continued employment. This reflects the company’s commitment to attracting talent within the biopharmaceutical sector.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced interim data from its Phase 1/2 study of GTX-102 for Angelman syndrome, showing good tolerability and clinical activity across multiple domains. The UK and Canadian health authorities have approved dose escalation to higher amounts, starting at 7.5 mg and reaching up to 14 mg. Ultragenyx has also completed a $75 million acquisition of GeneTx. Early results indicate significant improvements in clinical symptoms, with no treatment-related serious adverse events noted.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the sale of 30% of its royalty interest from Kyowa Kirin on Crysvita sales in the U.S. and Canada to OMERS for $500 million. This deal, effective from April 2023, caps total payments at 1.45 times the purchase price. Crysvita has achieved over $1.3 billion in net sales in its first four years, marking a successful launch. The proceeds from this non-dilutive financing will support ongoing commercialization and clinical development activities.
NOVATO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, focused on rare genetic diseases, announced that CEO Emil D. Kakkis and CFO Mardi Dier will present at the Goldman Sachs Global Healthcare Conference on June 16, 2022, at 10:00 AM PDT in Palos Verdes, CA. The live and archived webcast will be available on the company’s website for 90 days. Ultragenyx aims to develop novel therapies for rare diseases with unmet medical needs, showcasing a commitment to effective and timely drug development.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the Jefferies Global Healthcare Conference on June 8, 2022, at 2:30 PM ET, in New York. The presentation will focus on the company's commitment to developing therapies for serious rare genetic diseases. A live and archived webcast will be available on their website for 90 days post-event. Ultragenyx aims to deliver effective treatments efficiently, addressing high unmet medical needs in rare diseases.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) revealed promising long-term efficacy and safety data for its investigational gene therapies DTX401 and DTX301 during recent presentations. Phase 1/2 studies show DTX401 for Glycogen Storage Disease Type Ia (GSDIa) sustained responses for over 3.5 years, with 70% mean reduction in cornstarch intake. DTX301 for Ornithine Transcarbamylase (OTC) deficiency demonstrated durable metabolic control for over four years, with significant improvements in patient responses. No serious adverse events reported across both studies, highlighting the therapies’ safety profiles.
Ultragenyx Pharmaceutical (NASDAQ: RARE) and Abeona Therapeutics (NASDAQ: ABEO) have entered into an exclusive license agreement for the gene therapy ABO-102 (now UX111) for treating Sanfilippo syndrome type A (MPS IIIA). Ultragenyx will oversee the program, while Abeona is eligible for tiered royalties up to 10% on net sales post-approval. The ongoing Transpher A trial shows promising interim results, indicating preserved neurocognitive development and no serious adverse events. The therapy has received multiple designations from the FDA and EMA, highlighting its potential in a field with high unmet medical needs.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that they will present significant data from their investigational gene therapy programs at the ASGCT 25th Annual Meeting, scheduled for May 16-19, 2022. Key presentations include safety and efficacy results from DTX301 and DTX401 clinical trials. Notable sessions include oral presentations on Ornithine Transcarbamylase Deficiency and Glycogen Storage Disease Type Ia. Additionally, the company will showcase advancements in their manufacturing platform, Pinnacle PCL™. CEO Emil D. Kakkis will speak on accelerated approval for gene therapies.